Tirzepatide Linked to Reduced Cardiovascular Risk Post-Intervention
Tirzepatide is associated with reduced cardiovascular risks and improved outcomes in patients undergoing PCI and TAVR, according to new research.
02 May 2026
Mounjaro: Type 2 Diabetes Treatment with Thyroid Cancer Risk
Mounjaro treats type 2 diabetes but has an FDA boxed warning for potential thyroid cancer risk, especially with certain medical histories.
02 May 2026
GLP-1 Study Finds Differences in Lean Mass Loss
GLP-1 study reports semaglutide preserved lean mass better than tirzepatide, with a 2% higher lean mass loss on tirzepatide over 12 months.
28 Apr 2026
